Skip to main navigation Skip to search Skip to main content

Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen

  • Emilia Sánchez Ruiz
  • , Rebeca Lahoz
  • , Antoni Noguera
  • , Núria Rovira
  • , Albert Català-Temprano
  • , Rafael Jiménez
  • , Clàudia Fortuny

Research output: Indexed journal article Article

23 Citations (Scopus)

Abstract

Recent updates of the guidelines on the prevention of human immunodeficiency virus mother-to-child transmission have shortened the neonatal zidovudine prophylactic regimens from 6 to 4 weeks. We present a prospective observational study in a large cohort of mother-infant pairs and report that the 4-week regimen allows an earlier recovery of the anemia in these otherwise healthy infants.
Original languageEnglish
Pages (from-to)376-379
Number of pages4
JournalPediatric Infectious Disease Journal
Volume29
Issue number4
DOIs
Publication statusPublished - 1 Apr 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Hematologic toxicity
  • Human Immunodeficiency virus
  • Pediatrics
  • Neonatal prophylaxis
  • Zidovudine

Fingerprint

Dive into the research topics of 'Antiretroviral-related hematologic short-term toxicity in healthy infants: implications of the new neonatal 4-week zidovudine regimen'. Together they form a unique fingerprint.

Cite this